Table 1 Baseline characteristics of each illness category.

From: Metabolomic and gut microbiome profiles across the spectrum of community-based COVID and non-COVID disease

 

Asymptomatic

Acute COVID-19 (≤ 7 days)

Ongoing Symptomatic COVID-19 (28–83 days)

Post COVID-19 Syndrome (≥ 84 days)

Non-COVID-19 illness (28–83 days)

Non-COVID-19 illness (≥ 84 days)

n

Col %

n

Col %

n

Col %

n

Col %

n

Col %

n

Col %

Total

307

 

1147

 

652

 

180

 

239

 

48

 

Age (mean, sd)

58.1

(10.2)

53.2

(12.0)

53.1

(11.2)

53.6

(11.5)

53.7

(11.0)

58.1

(9.2)

Age Groups

 < 30

5

1.6%

41

3.6%

19

2.9%

7

3.9%

5

2.1%

0

0.0%

 30–39

9

2.9%

130

11.3%

65

10.0%

16

8.9%

26

10.9%

1

2.1%

 40–49

47

15.3%

219

19.1%

133

20.4%

36

20.0%

42

17.6%

7

14.6%

 50–59

92

30.0%

401

35.0%

247

37.9%

67

37.2%

88

36.8%

18

37.5%

 60–69

122

39.7%

259

22.6%

151

23.2%

41

22.8%

63

26.4%

17

35.4%

 70 +

32

10.4%

95

8.3%

37

5.7%

13

7.2%

14

5.9%

5

10.4%

Sex

 Male

68

22.1%

251

21.9%

144

22.1%

35

19.4%

39

16.3%

12

25.0%

 Female

238

77.5%

892

77.8%

505

77.5%

141

78.3%

200

83.7%

36

75.0%

Other/PFNTS

1

0.3%

4

0.3%

3

0.5%

4

2.2%

0

0.0%

0

0.0%

BMI (median, IQR)

25.3

(25.6–28.4)

25.2

(22.7–28.6)

25.5

(22.9–29.4)

26.3

(23.4–31.9)

25.7

(22.7–30.3)

26.2

(22.5–29.7)

 < 18.5

1

0.3%

10

0.9%

5

0.8%

5

2.8%

6

2.5%

1

2.1%

 18.5–24.9

141

45.9%

547

47.7%

287

44.0%

59

32.8%

103

43.1%

18

37.5%

 25–29.9

111

36.2%

369

32.2%

210

32.2%

62

34.4%

65

27.2%

18

37.5%

 30.0–34.9

36

11.7%

139

12.1%

95

14.6%

33

18.3%

42

17.6%

7

14.6%

 35 +

13

4.2%

75

6.5%

49

7.5%

21

11.7%

21

8.8%

4

8.3%

Missing

5

1.6%

7

0.6%

6

0.9%

0

0.0%

2

0.8%

0

0.0%

Confirmed by Swab Test at symptom onset (n, %)

15

4.9%

567

49.4%

315

48.3%

84

46.7%

163

68.2%

28

58.3%

  1. n: number; sd: standard deviation; IQR: Inter-quartile range. Participants not confirmed by swab testing at symptom onset were confirmed by antibody testing-further details in methods.